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Abstract
Background: Because of the emergence of chloroquine resistance in Mali, artemether-lumefantrine (AL) or artesunate-
amodiaquine (AS+AQ) are recommended as first-line therapy for uncomplicated malaria, but have not been available in
Mali until recently because of high costs.
Methods: From July 2005 to January 2006, a randomized open-label trial of three oral antimalarial combinations, namely
AS+AQ, artesunate plus sulphadoxine-pyrimethamine (AS+SP), and amodiaquine plus sulphadoxine-pyrimethamine
(AQ+SP), was conducted in Faladje, Mali. Parasite genotyping by polymerase chain reaction (PCR) was used to distinguish
new from recrudescent Plasmodium falciparum infections.
Results: 397 children 6 to 59 months of age with uncomplicated Plasmodium falciparum malaria were enrolled, and
followed for 28 days to assess treatment efficacy. Baseline characteristics were similar in all three treatment groups. The
uncorrected rates of adequate clinical and parasitologic response (ACPR) were 55.7%, 90.8%, and 97.7% in AS+AQ,
AS+SP, and AQ+SP respectively (p < 0.001); after PCR correction ACPR rates were similar among treatment groups:
95.4%, 96.9%, and 99.2% respectively (p = 0.17). Mean haemoglobin concentration increased across all treatment groups
from Day 0 (9.82 ± 1.68 g/dL) to Day 28 (10.78 ± 1.49 g/dL) (p < 0.001), with the greatest improvement occurring in
children treated with AQ+SP. On Day 2, the prevalence of parasitaemia was significantly greater among children treated
with AQ+SP (50.8%) than in children treated with AS+AQ (10.5%) or AS+SP (10.8%) (p < 0.001). No significant
difference in gametocyte carriage was found between groups during the follow-up period.
Conclusion: The combination of AQ+SP provides a potentially low cost alternative for treatment of uncomplicated P.
falciparum infection in Mali and appears to have the added value of longer protective effect against new infection.
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Background
For more than five decades, chloroquine (CQ) has been
the main drug for the treatment of uncomplicated malaria
in Mali. The emergence of Plasmodium falciparum resist-
ance to CQ has challenged control efforts in Mali, where
recent studies indicate that the adequate clinical and par-
asitological response (ACPR) to CQ is estimated to be less
than 50% in children aged between six months and nine
years [1,2] in different endemic settings of the country.
These data compelled the Ministry of Health to change to
artemisinin-based combination therapy (ACT) for first-
line treatment of uncomplicated malaria, in line with the
recommendations of the Word Health Organization
(WHO) [3]. The two combinations selected were artesu-
nate-amodiaquine (AS+AQ) and artemether-lumefan-
trine (AL), which were found to be efficacious and well
tolerated in the country [4,5].
Unfortunately, the implementation of ACT among the
most vulnerable populations living in highly malarious
rural areas has been hampered by the limited availability
and high cost of the new drugs. In Mali, the healthcare sys-
tem operates on local cost-recovery, and current prices for
ACT in public sector range from 700–1,500 CFA
(US$1.50–4.0). Thus, the majority of patients did not
have access to the newly recommended treatment and
continued to use chloroquine despite its low efficacy.
Therefore, there was a need to test other combination
therapies already available in the country before ACT
became more widely available. WHO recommendations
allow for the use of non-artemisinin combination treat-
ment regimens for the treatment of uncomplicated
malaria in settings where the component drugs are effica-
cious and well tolerated. Data from several settings have
demonstrated a similar efficacy between ACT and the
combination of amodiaquine plus sulphadoxine-
pyrimethamine (AQ+SP) [6,7].
In Mali, SP is still efficacious (in vivo efficacy of ~95%)
according to two separate studies [2,8] and is currently
authorized only for intermittent preventive treatment dur-
ing pregnancy (IPTp) [9]. There are data showing good
efficacy (adequate clinical and parasitological response
(ACPR) of 99.1%) of AQ in combination with AS [4]. We
therefore hypothesized that the combination AQ+SP
would be efficacious as suggested by earlier studies in
other settings [10-12], and designed a three-arm in vivo
efficacy study to evaluate this non-artemisinin containing
combination and compare it with two artemisinin-con-
taining combinations (AS+AQ and AS+SP).
Methods
Study site and population
The study was conducted in the rural village of Faladje,
located 80 km Northwest of Bamako. The village has a
Catholic mission health center that serves 23,000 inhabit-
ants living in the village and surrounding areas. Malaria
transmission is seasonal (July-October) with a peak in
October. Most of the population is of the Bambara ethnic
group with agriculture as the main occupation.
Study design and procedures
This was a randomized single-blind trial, conducted
between July 2005 and January 2006, that included chil-
dren between six and 59 months of age living in Faladje.
After written informed consent of patients' parents or
guardians, study subjects were enrolled if they fulfilled the
following WHO in vivo criteria [13]: i) microscope diag-
nosed mono-infection with P. falciparum with a parasitae-
mia of 2,000 – 200,000/μl, ii) axillary temperature of ≥
37.5°C, iii) haemoglobin ≥ 5 g/dL, iv) absence of febrile
illness caused by diseases other than malaria, vi) absence
of danger signs (inability to stand or drink, convulsions,
lethargy or persistent vomiting). Allocation to treatment
groups was done according to block randomization
(block size of 20); patients were not informed of the drug
received.
Treatment was administered according to body weight at
the following doses: AQ: 10 mg/kg/day from day 0 to day
2; AS: 4 mg/kg/day from day 0 to day 2; SP: 25 mg/kg of
sulphadoxine and 1.25 mg/kg of pyrimethamine in single
dose on day 0. All drugs were administered directly by the
study team and the child was observed for 30 minutes. If
vomiting occurred before 30 minutes, the dose was
repeated; for vomiting after 30 minutes, a half-dose was
administered. In the case of persistent vomiting, the child
was referred to a health center for rescue treatment with
intramuscular or intravenous quinine and withdrawn
from the study.
After the day of enrollment (day 0), the child was assessed
on days 1, 2, 7, 14, and 28. Parents/guardians were
encouraged to come to the clinic at any time when the
child was sick.
Laboratory procedures
Capillary blood was obtained by fingerpick, thick and
thin blood films were prepared and stained with 4%
Giemsa for 20 minutes. Parasite densities were deter-
mined from thick blood smears by counting the number
of asexual parasites per 300 WBCs assuming a WBC count
of 7,500/μl. The same estimation method was used to cal-
culate gametocyte density. Slides were read by an experi-
enced medical microscopist, who was blinded to the
treatment allocation. A negative blood film was defined as
a slide with no parasites after review of 100 fields. Thin
blood films were read only for parasite species determina-
tion. Ten percent of slides were read by a second reader,Malaria Journal 2009, 8:5 http://www.malariajournal.com/content/8/1/5
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blinded to initial results. Discordant slides were read by a
third microscopist.
Blood haemoglobin concentration was measured using a
portable photometer (HemoCue: Anglholm, Sweden) on
days 0, 14, 28 and any day of failure. Anaemia was defined
as haemoglobin < 11.0 g/dl.
To distinguish recrudescence from new infection, molecu-
lar genotyping techniques were used for patients who
failed after day 7. At enrollment and during the follow-up
visits, blood spots were obtained on filter papers and eval-
uated at the Molecular Epidemiology and Drug Resistance
Unit of the Malaria Research and Training Center in
Bamako. Molecular analysis was done according to the
following scheme: paired blots (from day 0 and the day of
parasitaemia recurrence) were analysed by nested PCR of
parasite merozoite surface proteins (MSP1 and MSP2)
and microsatellite (CA1), to distinguish between new
infection and recrudescence as previously described [5].
Study endpoints classification
Treatment outcomes were classified following the 2003
WHO antimalarial drug efficacy guidelines [13]. Early
Treatment Failure (ETF) was defined as one of the follow-
ing: a) Danger signs/severe malaria on day 1, 2 or 3 with
parasitaemia; b) parasite density on day 2 greater than at
day 0; c) parasitaemia at day 3 with fever (axillary temper-
ature ≥ 37.5°C); d) parasite density at day 3 equal or
greater than 25% of that at day 0. Late Clinical Failure
(LCF) was defined as danger signs/severe malaria or para-
sitaemia with fever occurring from day 4 to day 28 with-
out previously meeting the criteria of ETF. Late
Parasitological Failure (LPF) was defined as parasitaemia
without fever from day 4 to day 28 and without previously
meeting any criteria of ETF or LCF. An Adequate Clinical
and Parasitological Response (ACPR) was defined as the
absence of parasitaemia by day 28 without previously
meeting the any criteria for ETF, LCF, or LPF. Outcomes
measured were efficacy rates at day 28 with and without
PCR adjustment. Other outcomes measured were anemia
Table 1: Baseline characteristics of children enrolled in antimalarial in vivo efficacy study, Faladje, Mali.
Characteristics AS+AQ N = 133 AS+SP N = 132 AQ+SP N = 132
Mean age ± S.D. (months) 34.49 ± 15.97 36.08 ± 15.97 37.56 ± 16.07
Range 6–59 6–59 8–59
Male gender, n (%) 72 (54.1) 64 (48.8) 82(62.1)
Mean weight ± SD (kg) 12.76 ± 3.30 12.77 ± 3.42 13.21 ± 3.49
Range 6.30–23.70 6–19.6 7.70–21.7
Mean height ± SD (cm) 92.05 ± 12.88 92.86 ± 14.18 94.39 ± 14.12
Range 63–115 64–120 65–133
Mean axillary temperature ± SD(°C) 38.59 ± .77 38.52 ± .78 38.58 ± .76
Range 37.5–40.2 37.5–40.6 37.5–40.8
Palpable spleen, n (%) 38(28.6) 40(30.3) 49 (37.1)
Mean haemoglobin ± SD (g/dl) 9.83 ± 1.80 9.71 ± 1.67 9.98 ± 1.59
Haemoglobin < 11 g/dl, n (%) 93(69.9) 102(77.3) 97(73.5)
GMPD/μl 24,113.4 22,846.8 24,051.7
Prior antimalarial use, n (%) 11(8.3) 4(3) 7(5.3)
Disease duration <= 1 day, n (%) 83(62.4) 92(69.7) 80(60.6)
Gametocyte carriage n (%) 1(0.8) 8 (6.1) 1(0.8)
AS+AQ, artesunate + amodiaquine; AS+SP, artesunate + sulphadoxine-pyrimethamine;
AQ+SP, amodiaquine + sulphadoxine-pyrimethamine. S.D, Standard deviation:
G/dl: Grams per deciliter
GMPD/μl: Geometric Mean Parasite Density per microliter.
P-values (not shown) were calculated from 2 × 3 X2 test, (for categorical variables) and by KruskalWallis test (for continuous variables with non-
normal distributions). Groups were not statistically different, except for gametocyte carriage (p = 0.006).Malaria Journal 2009, 8:5 http://www.malariajournal.com/content/8/1/5
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(haemoglobin < 11.0 g/dl) as well as fever, parasite, and
gametocyte clearance times.
Ethical approval
The protocol was approved by the ethical committee of
the University of Bamako Faculty of Medicine, Pharmacy,
and Odonto-stomatology (FMPOS) and the Institutional
Review Board of the United States Centers for Disease
Control and Prevention before the study was started.
Overall community and local authorities' permission
were also obtained in addition to parent or guardian
informed consent, according to procedures described ear-
lier [14].
Data entry and analysis
Data were double entered using Microsoft ACCESS and
statistical analysis was performed using SPSS version 11.0
(Chicago, IL, USA). Baseline characteristics of subjects
among groups were compared using the chi-square test
for categorical variables and Mann-Whitney U-test for
non-normally distributed continuous variables. The pri-
mary analysis was per protocol. Proportion of patients
failing treatment was compared across groups using the
chi-square test. Paired t test was used to estimate haemo-
globin increase from baseline to different time points of
regular follow-up. To account for multiple comparisons
the results of the tests were considered statistically signifi-
cant when p < 0.017 (0.05 divided by 3).
Results
From July 2005 to January 2006, 876 children 6 to 59
months of age were screened for study entry (Figure 1);
397 were enrolled in the study and assigned to treatment
arms (Table 1). Baseline characteristics were similar across
the three treatment groups except for gametocyte carriage,
which was more common among those in the AS+SP
group. During follow-up, five children dropped out
before day 14 because of travel, and one child whose par-
asitaemia had resolved died at day 7; the cause of death
was unknown (Figure 1). There was no difference between
groups regarding the rate of loss to follow-up. At day 28,
391 children were evaluable: 131, 130, and 130 in
AS+AQ, AS+SP, and AQ+SP treatment arms respectively.
Before PCR correction, ACPR was 55.7%, 90.8% and
97.7% in the AS+AQ, AS+SP, and AQ+SP arms respec-
tively, and these differences were statistically significant
(Table 2). After PCR adjustment, all treatment arms had
an ACPR of > 95%, with no statistical difference among
the groups (Table 2).
At day 14, the proportion of children with anemia was sig-
nificantly higher in AS+SP group (77.5%) when com-
pared with AQ+SP (61.4%; p = 0.0046), but not with
AS+AQ (65.9%; p = 0.030); the difference between the
AS+AQ and AQ+SP groups was not statistically significant
(Table 3). Overall, the mean haemoglobin was signifi-
cantly increased in all treatment groups at day 14 (10.17
± 1.47 g/dl) when compared with day 0 (9.84 ± 1.68 g/dl)
(p < 0.01) and the greatest increase was observed among
Table 2: Therapeutic efficacy of artesunate + amodiaquine, artesunate + sulphadoxine-pyrimethamine, and amodiaquine + 
sulphadoxine-pyrimethamine among children with uncomplicated malaria in Faladje, Mali
Characteristics AS+AQ (N= 131) AS+SP (N = 130) AQ+SP (N = 130)
PCR uncorrected responses on day 28: n (%)
Failures 58 (44.3) 12 (9.2) 3(2.3)
ETF 0 (0) 2(1.5) 0(0)
LCF 14 (10.7) 2(1.5) 1(0.8)
LPF 44 (33.6) 8(6.2) 2(1.5)
*ACPR 73 (55.7) 118 (90.8) 127(97.7)
PCR corrected responses on day 28: n; %
Failures 6 (4.6) 4 (3.1) 1 (0.8)
ETF 0 (0) 2(1.6) 0(0)
LCF 2(1.5) 1(0.8) 0(0)
LPF 4(3.1) 1(0.8) 1 (0.8)
**ACPR 124(95.4) 125(96.9) 129(99.2)
AS+AQ, artesunate + amodiaquine; AS+SP, artesunate + sulphadoxine-pyrimethamine;
AQ+SP, amodiaquine + sulphadoxine-pyrimethamine
ETF, early treatment failure; LCF, late clinical failure; LPF, late parasitological failure; ACPR, adequate clinical and parasitological response.
Failures are the combination of ETF, LCF, and LPF. Percentages are rounded to achieve 100% of totals.
*X2 test: p < 0.001, AS+AQ vs. AS+SP; p < 0.001, AS+AQ vs. AQ+SP; p = 0.016, AS+SP vs. AQ+SP
**X2 test: p = 0.17 for the comparison of the three treatment arms.Malaria Journal 2009, 8:5 http://www.malariajournal.com/content/8/1/5
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children treated with AQ+SP (0.45 g/dl) followed by
AS+AQ (0.34 g/dl) and AS+SP (0.18 g/dl) (Table 3).
At day 28, the proportion of patients with anemia was
54.3%, 59.8%, and 46.2% in the AS+AQ, AS+SP, and
AQ+SP groups respectively, but these differences were not
statistically significant. Overall, the mean hemoglobin
was significantly increased in all treatment groups at day
28 (10.78 ± 1.48 g/dl) when compared with day 0 (9.84 ±
1.68 g/dl) (p < 0.001); and the most significant increase
was observed among children in AQ+SP (1.07 g/dl) group
followed by AS+AQ (0.95 g/dl) and by AS+SP (0.79 g/dl)
groups.
The proportion of patients with fever decreased from Day
0 (100%) to Day 1 (5.8%), Day 2 (2%), and Day 3 (1.5%)
across all treatment arms. No difference was found among
treatment groups at scheduled follow-up points with
regard to the proportion of patients with fever. There were
sharp declines in the proportion of children with parasi-
taemia from day 0 to day 2 in the AS+AQ (10.5%) and
AS+SP (10.7%) groups, but not in AQ+SP (50.7%), (p <
0.001). By day 3, 1.5%, 0.8%, and 6% of patients were
still parasitaemic in the AS+AQ, AS+SP, and AQ+SP
groups respectively (p = 0.018) (Table 3).
From day 0 to day 3, there was an increase of the propor-
tion of gametocyte carriage followed by a decrease from
day 3 to day 28 where that proportion approached zero.
No statistical difference in gametocyte carriage between
study arms was found at day 3 (p = 0.03) or day 28 (p =
0.16) (Figure 2).
Discussion
This study illustrated that the non-artemisinin containing
combination AQ+SP was as efficacious as the artemisinin-
Profile of children screened, enrolled, and completing study protocol Figure 1
Profile of children screened, enrolled, and completing study protocol.
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based combinations AS+AQ and AS+SP for the treatment
of uncomplicated P. falciparum malaria in children aged 6
to 59 months in Faladje, Mali. AQ+SP showed the highest
ACPR at day 28 without PCR correction. After PCR correc-
tion, AQ+SP demonstrated the highest ACPR, although
the difference was not statistically significant. These data
corroborate those from other countries, which show the
equal or superior efficacy of AQ+SP when compared with
AS+AQ [15,16] or AS+SP [17]. These data suggest that
AQ+SP provided greater protection against new infections
during the 28-day follow-up period than either AS+AQ or
AS+SP. The prevention of new infection provided by
AQ+SP is probably due to the long elimination half-lives
of the component drugs; while in AS+AQ, the arteminisin
is quickly eliminated, providing no post-treatment proph-
ylaxis [18].
Children treated with AQ+SP had a lower prevalence of
anaemia on days14 and 28 than children treated with
AS+AQ or AS+SP. Anaemia prevalence appeared to track
with parasitaemia prevalence, suggesting that the combi-
nation of two longer half-life drugs in AQ+SP may provide
longer protection against new infections and subsequent
anemia. While mean haemoglobin concentration on day
28 was higher among children treated with AQ+SP, this
difference was not statistically significant. This is in con-
sistent with prior studies, which have demonstrated simi-
lar mean haemoglobin concentration between AS+AQ
and AQ+SP [16,17].
The two artemisinin-based combinations, AS+AQ and
AS+SP, showed faster parasite clearance than AQ+SP, but
all three regimens resulted in prompt fever reduction.
Despite the lower proportion of fever and parasitaemia
observed during the first three days after treatment in the
two ACT groups, there were more new infections in these
groups than in the non-ACT group (AQ+SP). A greater risk
of new infection following treatment with AS+AQ when
compared with the AQ+SP has been reported earlier in
low [12] and high transmission areas [11,19]. In Mali,
AS+AQ, co-blistered but not co-formulated, has been
introduced nationally as first-line therapy for uncompli-
cated malaria. However, there are concerns about patient
compliance with the large number of tablets, and there is
anecdotal evidence that patients may be taking the artesu-
nate pills as monotherapy. With support from the Global
Fund, the Malian Ministry of Health is providing AS+AQ
free to children less than five years of age. Widespread
implementation of ACTs in this vulnerable population
should produce a significant reduction in malaria mortal-
ity and morbidity in Mali. However, it is essential to con-
tinue monitoring the efficacy of this regimen, and to
consider alternatives should evidence of resistance
develop.
Table 3: Haemoglobin concentration, anaemia, and parasitaemia among participants in an antimalarial in vivo efficacy study, Faladje, 
Mali.
Characteristics AS+AQ AS+SP AQ+SP
Day 0
N1 3 3 1 3 2 1 3 2
Mean Haemoglobin ± S.D (g/dl) 9.83 ± 1.8 9.71 ± 1.59 9.98 ± 1.59
Anaemia (< 11 g/dl), n (%) 93 (69.9) 102 (77.3) 97 (73.5)
Day 14
N1 3 1 1 3 0 1 3 0
§Mean Haemoglobin ± S.D (g/dl) 10.17 ± 1.5 9.89 ± 1.40 10.43 ± 1.49
*Anaemia (< 11 g/dl), n (%) 87 (65.9) 100 (77.5) 81 (61.4)
Day 28
N1 0 5 1 2 7 1 3 0
§SMean Haemoglobin ± S.D (g/dl) 10.78 ± 1.49 10.5 ± 1.40 11.05 ± 1.52
**Anaemia (< 11 g/dl), n (%) 57(54.3) 76 (59.8) 60 (46.2)
Parasitaemia, n (%)
€Day2 14(10.5) 14(10.7) 67(50.7)
€Day3 2(1.5) 1(0.8) 8 (6.0)
Day14 5(3.8) 2(1.6) 2(1.5)
€Day28 31(29.5) 9(7.1) 3(2.3)
AS+AQ, artesunate + amodiaquine; AS+SP, artesunate + sulphadoxine-pyrimethamine; AQ+SP, amodiaquine + sulphadoxine-pyrimethamine
*X 2 test: p = 0.014 overall (2 × 3); p = 0.030, AS+SP vs. AS+AQ; p = 0.0046, AS+SP vs. AQ+SP; p = 0.48, AS+AQ vs. AQ+SP.
**X 2 test: p = 0.08 overall (2 × 3); p = 0.027, AQ+SP vs. AS+SP; p = 0.21, AQ+SP vs. AS+AQ; p = 0.39, AS+AQ vs. AS+SP
§Paired t-test comparison day 0 vs. day 14: overall, p < 0.01; AQ+SP, p = 0.001; AS+AQ, p = 0.011; AS+SP, p = 0.033.
§SPaired t-test comparison day 0 vs. day 28: overall, p < 0.001; AQ+SP, p < 0.001; AS+AQ, p < 0.001; AS+SP, p < 0.001
€X 2 test: overall (2 × 3); Time points showing difference among the three groups: Day 2, p < 0.001; Day3, p = 0.017; Day 28, p < 0.001.Malaria Journal 2009, 8:5 http://www.malariajournal.com/content/8/1/5
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Conclusion
The combination of AQ+SP provides a potentially low-
cost alternative for treatment of uncomplicated P. falci-
parum infection in Mali, and appears to have the added
value of longer protective effect against new infections.
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